Trials / Unknown
UnknownNCT01839539
Study of DC-CIK to Treat Colorectal Cancer
Phase Ⅱ Study of Dendritic and Cytokine-induced Killer Cells (DC-CIK) Treatment in Patients With Stage Ⅲ Colorectal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Guangxi Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of dendritic and cytokine-induced killer cells (DC-CIK) for colorectal cancer (CRC).
Detailed description
60 patients with stage Ⅲ CRC, who had received neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, and got complete response (CR), will be randomly divided into group A (receive DC-CIK treatment) or group B (just regularly follow up), and the randomize ratio will be 1:1. Patients in group A will receive 2-3 cycles of DC-CIK cells treatment (every 4 weeks). Patients in group B will have no anti-tumor therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | dendritic and cytokine-induced killer cells |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2018-03-01
- Completion
- 2018-03-01
- First posted
- 2013-04-25
- Last updated
- 2013-04-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01839539. Inclusion in this directory is not an endorsement.